Novasep has entered an agreement with Celladon, a clinical-stage biotechnology company, to prepare and supply the API for Mydicar, in a deal valued at €4.7 million. MYDICAR is a genetically-targeted enzyme replacement therapy for advanced heart failure, and is currently in several Phases of development, including a Phase IIb study in the U.S.   Novasep will provide scale-up and pre-validation studies. The agreement also includes engineering enhancements Novasep will make at its Seneffe (Belgium)...